Clinical Trial Update: A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis [Phase 3]

View source ↗

Summary

Akero Therapeutics is conducting a Phase 3 trial of efruxifermin in adults with noncirrhotic NASH/MASH with fibrosis; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Steatohepatitis
• Nonalcoholic Steatohepatitis

Drugs mentioned

• efruxifermin (efruxifermin)

Snippet

Sponsor: Akero Therapeutics, Inc | Conditions: NASH With Fibrosis, MASH With Fibrosis | Phase 3 | Status: RECRUITING